Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado, et al.
The Lancet (2021) Vol. 397, Iss. 10291, pp. 2253-2263
Open Access | Times Cited: 448

Showing 1-25 of 448 citing articles:

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Betty Raman, David A. Bluemke, Thomas F. Lüscher, et al.
European Heart Journal (2022) Vol. 43, Iss. 11, pp. 1157-1172
Open Access | Times Cited: 526
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19
Alex C. Spyropoulos, Mark Goldin, Dimitrios Giannis, et al.
JAMA Internal Medicine (2021) Vol. 181, Iss. 12, pp. 1612-1612
Open Access | Times Cited: 405
2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
Tze‐Fan Chao, Boyoung Joung, Yoshihide Takahashi, et al.
Thrombosis and Haemostasis (2021) Vol. 122, Iss. 01, pp. 020-047
Open Access | Times Cited: 363
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial
Michelle Sholzberg, Grace H. Tang, Hassan Rahhal, et al.
BMJ (2021), pp. n2400-n2400
Open Access | Times Cited: 317
A guide to immunotherapy for COVID-19
Frank L. van de Veerdonk, Evangelos J. Giamarellos‐Bourboulis, Peter Pickkers, et al.
Nature Medicine (2022) Vol. 28, Iss. 1, pp. 39-50
Open Access | Times Cited: 276
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium
Diana A. Gorog, Robert F. Storey, Paul A. Gurbel, et al.
Nature Reviews Cardiology (2022) Vol. 19, Iss. 7, pp. 475-495
Open Access | Times Cited: 251
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19
Jean M. Connors, Maria M. Brooks, Frank C. Sciurba, et al.
JAMA (2021) Vol. 326, Iss. 17, pp. 1703-1703
Open Access | Times Cited: 220
A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
Douglas B. Kell, Gert Jacobus Laubscher, Etheresia Pretorius
Biochemical Journal (2022) Vol. 479, Iss. 4, pp. 537-559
Open Access | Times Cited: 209
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
ISTH guidelines for antithrombotic treatment in COVID‐19
Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 10, pp. 2214-2225
Open Access | Times Cited: 145
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 142
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 128
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial
Eduardo Ramacciotti, Leandro Barile Agati, Daniela Calderaro, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 50-59
Open Access | Times Cited: 124
Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial
Usha Perepu, Isaac Chambers, Abdul Wahab, et al.
Journal of Thrombosis and Haemostasis (2021) Vol. 19, Iss. 9, pp. 2225-2234
Open Access | Times Cited: 120
Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19
Simin Florescu, Delia Stanciu, Mihaela Zaharia, et al.
JAMA (2022) Vol. 327, Iss. 13, pp. 1247-1247
Open Access | Times Cited: 108
Thromboprophylaxis in Patients With COVID-19
Lisa K. Moores, Tobias Tritschler, Shari B. Brosnahan, et al.
CHEST Journal (2022) Vol. 162, Iss. 1, pp. 213-225
Open Access | Times Cited: 79
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK
Ivan Chun Hang Lam, Carlos King Ho Wong, Ran Zhang, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102000-102000
Open Access | Times Cited: 72
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 69
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients
Bingwen Eugene Fan, Shiun Woei Wong, Christina Lai Lin Sum, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 7, pp. 915-923
Open Access | Times Cited: 67
Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association
Janice Y. Chyou, Ebrahim Barkoudah, Jonathan W. Dukes, et al.
Circulation (2023) Vol. 147, Iss. 15
Open Access | Times Cited: 51
Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19
Gregg W. Stone, Michael E. Farkouh, Anuradha Lala, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 18, pp. 1747-1762
Open Access | Times Cited: 49
Pharmacology of Heparin and Related Drugs: An Update
John Hogwood, Barbara Mulloy, R. Lever, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 2, pp. 328-379
Open Access | Times Cited: 47
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation
Tze‐Fan Chao, Boyoung Joung, Yoshihide Takahashi, et al.
Journal of Arrhythmia (2021) Vol. 37, Iss. 6, pp. 1389-1426
Open Access | Times Cited: 66
Editor's Choice – Update of the European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia in Light of the COVID-19 Pandemic, Based on a Scoping Review of the Literature
Vincent Jongkind, J J Earnshaw, Frederico Bastos Gonçalves, et al.
European Journal of Vascular and Endovascular Surgery (2021) Vol. 63, Iss. 1, pp. 80-89
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top